Biogen's Early-Stage Alzheimer's Data Continues to Impress Post author:Sam Post published:November 1, 2017 Post category:BioPharma ALZ’s researchers continue to see hope in Biogen’s aducanumab. Source: BioSpace You Might Also Like Biotechs Drool as VC Firm Andreessen Horowitz Doubles Down on the Life Sciences With New $450M Fund December 14, 2017 <b>NDA Group</b> Expands Service Offerings And Geographic Reach Appointing New Us Service Area Leaders And Head Of Business Development July 10, 2017 Reported Side Effects Raise Concerns for Regeneron’s Eylea February 21, 2018
Biotechs Drool as VC Firm Andreessen Horowitz Doubles Down on the Life Sciences With New $450M Fund December 14, 2017
<b>NDA Group</b> Expands Service Offerings And Geographic Reach Appointing New Us Service Area Leaders And Head Of Business Development July 10, 2017
